Physician profile
Cheryl B Fedel
NPI 1114215464
$2,016.50
in general payments reported to CMS, 2019-2025
20 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $324 · 2021: $280 · 2022: $346 · 2023: $116 · 2024: $296 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623 · Entertainment: $19.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.61 |
| Entertainment | $19.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $407.76 | 2019-2024 | Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $344.60 | 2019-2025 | Cequa |
| Alcon Vision LLC | $341.86 | 2019-2025 | Tryptyr, Precision7, Rhopressa |
| Johnson & Johnson Vision Care, INC. | $167.50 | 2019-2024 | |
| Oyster Point Pharma, INC. | $116.10 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $84.64 | 2019-2021 | |
| Allergan, INC. | $79.51 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $67.66 | 2024-2025 | Infuse |
| Shire North American Group INC | $60.39 | 2019 | |
| Sight Sciences, INC. | $58.81 | 2020-2022 | |
| Dompe US, INC. | $47.66 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $46.40 | 2022-2025 | Iyuzeh |
| Glaukos Corporation | $38.50 | 2022 | |
| Abbvie INC. | $32.66 | 2024 | |
| Harrow Eye, LLC | $30.68 | 2024 | Vevye |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $19.79 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $18.90 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $17.31 | 2025 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $16.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Fedel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.